Analysis: a first win, with the size of the win visible in the numbers
The claim that matters here is regulatory rather than statistical. ACACIA-HCM is the first Phase 3 trial to show significant improvement on both patient-reported and physician-assessed endpoints in non-obstructive HCM, a population that currently has no disease-directed therapy. For a supplemental application, that is the relevant bar, and both primary endpoints cleared their prespecified thresholds.
The effect sizes are worth reading alongside the p-values. The questionnaire difference of 3.0 points sits inside a confidence interval running from 0.5 to 5.5, and the exercise difference of 0.67 ml/kg/min inside an interval from 0.22 to 1.1. Both intervals exclude zero, which is what significance means, and both extend down to a lower bound close to zero. The endpoints that failed are the ones tracking hard outcomes and cardiac remodelling: time to first cardiovascular event returned a p-value of 0.678, with events in 22 patients on drug and 20 on placebo, and left atrial volume index missed at 0.058. The trial establishes symptomatic and functional benefit. It does not establish event reduction, and the company does not claim it does.
The safety numbers set the boundary the label already reflects. An ejection fraction drop below 50% in 10.5% of treated patients against 0.8% on placebo is the same mechanism that produced the boxed warning and the REMS programme in obstructive disease, and non-obstructive patients start from a different clinical baseline. That the events clustered before Week 12 and responded to diuretics is reassuring on management, not on incidence.
The public trial registry supplies the timeline against which the filing should be checked. ACACIA-HCM is registered as NCT06081894, listed as active but not recruiting with a start date in 2023, while MAPLE-HCM, the head-to-head trial against metoprolol in obstructive disease, is registered as NCT05767346 and listed as completed. The open-label extension FOREST-HCM, NCT04848506, is enrolling by invitation, and the paediatric study CEDAR-HCM, NCT06412666, is active but not recruiting. The company says most eligible ACACIA-HCM patients rolled into FOREST-HCM, which is where any longer-term durability data will come from, and the washout finding makes that extension the study to watch.
Commercially, the second indication would roughly define the size of the franchise, but the base is early. Product revenue of $25,334 thousand in the quarter against half-year operating cash use of $305.3 million shows a launch in its second quarter, not a business at scale. What a careful reader would look for next is the FDA’s acceptance of the supplemental application and any filing date, the FOREST-HCM data on whether the Week 36 effect holds, and whether the REMS requirements carry over to a population with less obstruction to treat.
What the documents say
Cytokinetics, Incorporated (Nasdaq: CYTK) reported on August 28, 2026 that ACACIA-HCM, its Phase 3 trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy, met both of its dual primary endpoints. The results were presented in a Hot Line session at the European Society of Cardiology Congress in Munich and published simultaneously in The New England Journal of Medicine. The company filed the announcement with the Securities and Exchange Commission as an exhibit to a Form 8-K.
Non-obstructive HCM has no approved drug that addresses the underlying disease. Aficamten, sold as MYQORZO, is already approved for the obstructive form. The South San Francisco company said it will submit a supplemental New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026.
What the trial measured
ACACIA-HCM randomised and treated 517 participants outside Japan on a one to one basis against placebo, with randomisation stratified by persistent atrial fibrillation and the presence of intracavitary obstruction. Entry required a resting left ventricular outflow tract gradient below 30 mmHg, a post-Valsalva gradient below 50 mmHg, ejection fraction of at least 60%, NYHA class II or III symptoms and a Kansas City Cardiomyopathy Questionnaire clinical summary score of 85 or lower. Dosing started at 5 mg daily with echocardiogram-guided escalation at weeks 2, 4 and 6 to 10, 15 or 20 mg, and escalation only if ejection fraction remained at or above 60%.
The two primary endpoints were the change from baseline to Week 36 in the questionnaire score and in maximal exercise performance, each tested at a significance threshold of 0.025. Both were met. The questionnaire score improved by a least squares mean of 11.4 points on aficamten against 8.4 on placebo, a difference of 3.0 with a p-value of 0.021. Peak oxygen uptake rose 0.64 ml/kg/min on aficamten and fell 0.03 on placebo, a difference of 0.67 with a p-value of 0.003.
Secondary endpoints split. Improvement of at least one NYHA class was reached by 108 patients, or 41.9%, on aficamten against 72, or 27.8%, on placebo. The composite exercise z-score and NT-proBNP both improved with p-values below 0.001. Two endpoints missed: change in left atrial volume index, at a p-value of 0.058, and time to first cardiovascular event, at 0.678.
Safety and the durability question
Serious adverse events occurred in 52 patients, or 20.2%, on aficamten against 38, or 14.7%, on placebo. Non-fatal adverse events leading to early discontinuation affected 18 patients, or 7.0%, on drug and 5, or 1.9%, on placebo. Ejection fraction fell below 50% in 27 patients, or 10.5%, on aficamten and in two, or 0.8%, on placebo; of those 27, 21 completed treatment at the same or a lower dose. All heart failure events on aficamten occurred during titration or before Week 12 and generally responded to a short course of diuretics.
Two findings on durability point in opposite directions. Patients still on treatment at 72 weeks showed a least squares mean improvement in the questionnaire score of 7.0 points, lower than the 11.4 recorded at Week 36. And after a four-week washout, the score on aficamten declined to match the placebo group.
A separate global efficacy analysis presented in the same session assessed exercise capacity, cardiac structure, cardiac biomarkers, diastolic function and symptom burden together. At 36 weeks all five improved against placebo with p-values below 0.001, and 53% of aficamten patients showed a clinical response on three or more measures against 13% on placebo. That analysis was published in Circulation.
The commercial position behind the trial
MYQORZO was approved by the FDA on December 19, 2025 for adults with symptomatic obstructive HCM and first reached patients in the first quarter of 2026. The European Commission approved it in February 2026, with first prescriptions in Germany in the second quarter, and China’s National Medical Products Administration approved it in December 2025, with supply there running through a licence to Sanofi.
The Form 10-Q for the quarter ended June 30, 2026 shows net product revenue of $25,334 thousand for the quarter and $30,123 thousand for the half, the company’s first product sales. Against that, net loss for the half was $404.8 million and net cash used in operations $305.3 million, with cash, cash equivalents and investments of $1.7 billion and an accumulated deficit of approximately $3.9 billion since inception. Under the Sanofi agreement Cytokinetics can earn up to $160.0 million of development and commercial milestones in obstructive and non-obstructive HCM, of which $10.0 million was earned in 2024 and $15.0 million in 2025, plus tiered royalties in the low to high teens on Chinese and Taiwanese sales.
The approval carries a boxed warning. MYQORZO reduces ejection fraction and can cause heart failure from systolic dysfunction, initiation is not recommended below an ejection fraction of 55%, and the drug is distributed only through a restricted programme under a Risk Evaluation and Mitigation Strategy requiring prescriber, patient and pharmacy enrolment.
